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Abstract
Background: The aim of the ACE-Obesity study was to determine the economic credentials of interventions which aim
to prevent unhealthy weight gain in children and adolescents. We have reported elsewhere on the modelled effectiveness
of 13 obesity prevention interventions in children. In this paper, we report on the cost results and associated methods
together with the innovative approach to priority setting that underpins the ACE-Obesity study.
Methods: The Assessing Cost Effectiveness (ACE) approach combines technical rigour with 'due process' to facilitate
evidence-based policy analysis. Technical rigour was achieved through use of standardised evaluation methods, a research
team that assembles best available evidence and extensive uncertainty analysis. Cost estimates were based on pathway
analysis, with resource usage estimated for the interventions and their 'current practice' comparator, as well as
associated cost offsets. Due process was achieved through involvement of stakeholders, consensus decisions informed
by briefing papers and 2nd stage filter analysis that captures broader factors that influence policy judgements in addition
to cost-effectiveness results. The 2nd stage filters agreed by stakeholders were 'equity', 'strength of the evidence',
'feasibility of implementation', 'acceptability to stakeholders', 'sustainability' and 'potential for side-effects'.
Results: The intervention costs varied considerably, both in absolute terms (from cost saving [6 interventions] to in
excess of AUD50m per annum) and when expressed as a 'cost per child' estimate (from <AUD1.0 [reduction of TV
advertising of high fat foods/high sugar drinks] to AUD31,553 [laparoscopic adjustable gastric banding for morbidly obese
adolescents]). High costs per child reflected cost structure, target population and/or under-utilisation.
Conclusion: The use of consistent methods enables valid comparison of potential intervention costs and cost-offsets
for each of the interventions. ACE-Obesity informs policy-makers about cost-effectiveness, health impact, affordability
and 2nd stage filters for important options for preventing unhealthy weight gain in children. In related articles cost-
effectiveness results and second stage filter considerations for each intervention assessed will be presented and analysed.
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Background
Obesity is now universally acknowledged as a major pub-
lic health problem, both in children and adults [1,2]. This
raises vital public health questions concerning what inter-
ventions are necessary to control the obesity epidemic;
whether our early endeavours to confront obesity are the
right choices; and whether they are sufficient to reverse the
obesity trends.
Scarcity of funds dedicated to public health also means
that difficult choices of what to fund to reverse the trend
in unhealthy weight gain are inevitable. While there is
nothing new about the task of making difficult choices in
health care, policy-makers are now discussing with
renewed interest the issue of how to set priorities which
are evidence-based. Often choices have been driven by
historical, political or commercial imperatives, but the
importance of 'evidence-based policy' is increasingly
being recognised [3]. Cost-effectiveness analyses can pro-
vide additional evidence-based information to help deci-
sion-makers set priorities and answer difficult questions
such as those posed above. But for cost-effectiveness anal-
ysis to be taken seriously, economic analysts also need to
address the broader concerns of decision-makers that go
beyond simple formulae-based decision-making.
In recognition of the need for 'evidence-based' informa-
tion to guide policy on obesity prevention, the Depart-
ment of Human Services in Victoria, Australia,
commissioned the Assessing Cost-Effectiveness in Obesity
(ACE-Obesity) project in 2004. The aim of the project was
to assist state and national policy-makers by providing
best available modelled evidence on the effectiveness and
cost-effectiveness of selected obesity prevention interven-
tions, particularly amongst children and adolescents.
ACE-Obesity followed earlier ACE studies in cancer [4],
heart disease [5], and mental health [6,7], where the ACE
approach was developed and successfully implemented.
The purpose of this paper is to overview the ACE approach
to priority setting, together with the specific methods used
in the ACE-Obesity study. In a companion paper [8],
detail was provided on the methods used to calculate the
likely impact of 13 obesity interventions on BMI, meas-
ured through changes in 'energy balance' and then conver-
sion to anticipated health gain (using Disability Adjusted
Life Years averted - DALYs). In this paper we complement
that overview of health benefit results and methods, by
providing an overview of cost results and key methodo-
logical issues associated with costing for the same 13
interventions. The bringing together of the benefits and
costs is dealt with in a separate paper on the cost-effective-
ness results (Moodie et al, 2009, as yet unpublished).
The ACE Approach to Priority Setting
While the importance and need for priority setting in
health care is generally accepted, the central question of
how priority setting is to be achieved remains contested.
There are a variety of approaches and models available,
offered from a range of disciplines [9]. There are models
developed by behavioural scientists based on achieving
consensus; by epidemiologists/clinicians based on needs
assessment; by philosophers based on notions of social
justice; and by economists based on achieving efficiency.
A central issue is the extent to which priority setting
approaches focus on 'technical analysis' or 'due process'
for their legitimacy [9]. The 'technical school' is character-
ised by a reliance on rational decision rules, data sets and
quantitative analysis. This school has in large part been
the preserve of health economists (pursuing the goal of
efficiency) and epidemiologists/clinicians (pursuing evi-
dence-based guidelines and/or needs-based equity). Deci-
sions are based on quantitative analysis and/or
application of the correct rules, whether efficiency and/or
equity focused. Provided one accepts these principles,
results should give guidance to decision-makers on how
services should be ranked.
In contrast, advocates of the 'due process' school question
the assumption that it is possible to devise 'rational' deci-
sion rules and see the technical approaches as based on a
simplistic view of the health care system. Here the task is
less to refine the technical basis of decision-making, than
to construct a process that enables proper debate and dis-
cussion to occur. This does not mean implicit rationing,
but instead a system whereby decisions are made explic-
itly and the reasoning behind specific judgements is
clearly explained.
The debate between the two schools, however, may be
drawn too starkly in the literature [9-11]. There is no
inherent conflict between action to provide more and bet-
ter information on the costs, outcomes and evidence base
for different interventions, and work to strengthen the
processes for debating that information and arriving at
judgements on priorities. The reality is that neither option
alone is likely to fulfil the theoretical and practical
requirements of an ideal approach to explicit priority set-
ting. Both elements need to be involved in any approach
to priority setting that is seeking strong theoretical foun-
dations and empirical validity. The 'ACE' approach
reflects our endeavours to develop such a joint approach.
On the technical side, the ACE methodology applies the
key economic concepts of 'opportunity cost'; 'marginal
analysis' and a 'clear concept of benefit' using standard-
ised evaluation methods clearly documented in an evalu-
ation protocol [9,12,13]. Undertaking the evaluations inBMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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this way as part of the priority setting exercise, addresses
the reservations expressed by many economists about the
simplistic use of league tables, where economic studies are
assembled from the literature with little regard to differ-
ences in methods, context and setting [13]. The key char-
acteristics of the ACE approach are:
• the rationale for the selection of interventions is
clearly explained;
￿ the evaluation methods are standardised, docu-
mented and open to scrutiny;
￿ the setting, context and comparator is common to all
interventions;
￿ country specific data are used, wherever possible, for
demography, health system costs and disease inci-
dence/prevalence patterns;
￿ information is assembled by a multi-disciplinary
research team, preparing briefing papers to a standard-
ised format agreed by a Working Group of stakehold-
ers;
￿ a range of results is reported (around point esti-
mates) reflecting explicitly the uncertainty of cost,
process, outcome and value estimates; and
￿ the incremental cost effectiveness ratios are placed
within a broader decision-making framework called
'2nd stage filter' analysis.
ACE Working Groups generally consist of stakeholders
recruited from topic experts, clinicians and practitioners,
relevant community organisations and policy-makers.
The ACE approach aims to give these stakeholders a
greater involvement in both the study design and conclu-
sions, as recommended by the Panel on Cost Effectiveness
in Health and Medicine [13]. The Working Group in ACE
studies has an important role in achieving balance
between the technical analyses and due process. On the
technical side members contribute in areas of their exper-
tise and discuss issues of method and evidence. On the
'due process' side, members ensure stakeholder interests
and views are articulated; facilitate sensible interpretation
of the technical analysis; assist with 'value' judgement
aspects of the 2nd filter analysis and help ensure transpar-
ency throughout the project.
Methods
The research question
The research question for the ACE-Obesity study was spec-
ified as:
What are the best options towards which state and national
resources should be directed to reduce unhealthy weight
gain in children and adolescents in Australia?
The reference year for all analyses was 2001, the latest year
for which all key data sets were available.
Study perspective
Given the nature of obesity interventions and their likely
settings in community-based facilities such as schools and
child care facilities, a broad 'societal perspective' was
adopted, but with a major focus on the health sector
implications. All known costs and outcomes of the inter-
ventions were identified and then either included or
excluded in the measurement stage, with reasons clearly
specified (such as availability of data or likelihood of
being impacted by the intervention).
Choice of comparator
One of the fundamental questions for economic evalua-
tion is 'what difference the option for change makes to
current policy?' Thus, the comparator to the interventions
selected as options for change in the ACE studies was 'cur-
rent practice' (refer Table 1). This recognises that resources
currently being used could be integrated into a coordi-
nated approach to the new intervention and/or that not
all the benefits could automatically be attributed to the
new intervention. This is often referred to as 'incremental
analysis', with the resulting cost-effectiveness ratios
referred to as incremental cost-effectiveness ratios (or
'ICERs'). In ACE-Obesity we modelled current practice as
a 'no intervention' comparator as very little activity, if any-
thing, was currently happening. Even where there was
some minor activity (e.g. in schools), there was consider-
able uncertainty as to what constituted 'current practice',
what it cost, and how effective it was. The associated dis-
ease management cost and health impacts of this 'no
intervention' comparator were modelled through time
and became the potential cost offsets and potential health
gains for the new interventions.
Target population
The actual Australian population of children and adoles-
cents (aged 5-19 years) in the year 2001 was used and fol-
lowed through time. The target groups within the
Australian population for which the interventions were
intended were clearly specified (refer Table 1). The rele-
vant target group varied depending on the specific inter-
vention; whether all persons in a particular age group, or
a specific group of people (for example, all 8-11 year olds
or overweight/obese 8-11 year olds).
Time horizon
The time horizon for providing an intervention reflected
its real-life application, but with costs and outcomesBMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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Table 1: Evaluation design frame for interventions chosen
Interventions1,2 and 
Setting
Target Population3 Cost Results Key cost issues
Gross Cost Net Cost 
(Net Saving)
Cost Child4
1. Active After School 
Communities Program 
[Child Care 5]. Runs 8 
weeks in each of the 4 
school terms.
Primary school children in 
Prep to Grade 6 (age 5-11 
years).
Number ≈ 99 000
$40.3 m
[UI: $28.6 m-$56.2 m]6
$36.5 m
[UI: $24.9 m-$52.6 m]
$407 i) Extensive & "lumpy" 
salary costs, particularly 
for regional physical 
activity co-ordinators; ii) 
sub-optimal capacity 
utilisation; iii) cost data 
modelled, not empirically-
based; and iv) BMI 
outcomes not 
commensurate with high 
cost structure.
2. Multi-faceted program, 
including education to 
improve nutrition & 
increase physical activity, 
without an active physical 
education component 
[School-based].
Children in primary 
school Grades 1 and 2 
(commencing in Grade 1, 
age 6 years).
Number ≈ 114 630
$24.3 m
[UI: $12.6 m-$39.2 m]
$9.0 m
[UI: net saving of $9.1 m 
to net cost of $31.7 m]
$211 i) Costs over 2 year-
period taken as 
representative 'annual 
cost' as reflects 
concomitant cohorts; ii) 
included central & school 
coordination costs for 
national program, but not 
teacher time (as 
integrated into 
curriculum); iii) assumed 
uptake by schools does 
not vary by type of school 
(public or private); and iv) 
parent involvement 
encouraged as part of 
program but not costed.
3. Multi-faceted program, 
including education to 
improve nutrition & 
increase physical activity, 
with an active physical 
education component 
[School-based].
Children in primary 
school Grades 1, 2 & 3 
(commencing Grade 1, 
age 6 years).
Number ≈ 114 630
$54.2 m
[UI: $26.9 m-87.5 m)
($14.0 m)
[UI: net saving of $41.9 m 
to net cost of $1.3 m]
$473 i) Costs over 3 year-
period taken as 
representative 'annual 
cost' as reflects 
concomitant cohorts; ii) 
included central & school 
coordination costs for 
national program, but not 
teacher time (as 
integrated into 
curriculum); iii) physical 
activity component may 
pose problem for primary 
schools without specialist 
physical education 
teachers; iv) assumed 
uptake by schools does 
not vary by type of school; 
and v) parent involvement 
encouraged but not 
costed.
4. Multi-faceted program 
[School-based] targeted at 
overweight and obese 
children.
Overweight or obese 
children aged 7-10 years 
(Grades 2-5) at combined 
primary/secondary school.
Number ≈ 17 000 over 4 
years 
(4 200 each year)
$2.2 m
[UI: $1.2 m to $4.1 m]
($1.2 m)
[UI: net saving of $5.7 m 
to net cost of $0.38 m]
$129 i) Modelled as 
implemented over 4 years 
rather than implementing 
it to everyone eligible 
every 4 years; ii) involves a 
peer-led program using 8th 
grade students, supported 
by counsellors, to help 
obese children in grades 
2-5; iii) counsellors costed 
as publicly funded 
psychologists employed 
on part-time basis 
(different to trial).
5. Education program to 
reduce consumption of 
carbonated (fizzy) drinks 
[School-based].
Children in primary 
school 2 to 6 (age 7-11 
years).
Number ≈ 595 000 
implemented over 5 years 
(119,000 each year)
$16.6 m
[UI: $7.6 m -$32.2 m]
($26.7 m)
[UI: net saving of $112.7 
m to net cost of $32.0 m]
$28 i) Capacity calculated on 
seeing 1/5th of schools 
each year, not all schools 
every year; ii) assumes 
each child receives 
intervention once during 
primary school; and iii) 
assumption of no 
additional school staff 
costs as sessions 
presented by trained 
project staff.BMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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6. Education program to 
reduce TV viewing 
[School-based].
Children in primary 
school Grades 3 & 4 (age 
8-10 years).
Number ≈ 268 600
$27.7 m
[UI: $12.7 m -$43.3 m]
($43.8 m)
[UI: net saving of $81.8 m 
to net saving of $6.6 m]
$103 i) Modelling included 
national/state project 
officers to implement 
national program and full 
training costs for teachers, 
but not teacher time in 
the classroom (as 
integrated into 
curriculum); ii) 50% of 
schools participate in any 
one year; iii) assumed 
uptake by schools does 
not vary by type of school 
(public or private); and iv) 
parent involvement 
encouraged as part of 
program but not costed.
7. TravelSmart Schools 
[Schools/neighbourhoods 
& community 
organisations7]
Children in primary 
school Grades 5 & 6 (age 
10-11 years).
Number ≈ 267 700
$13.3 m
[UI: $6.9 m -$22.8 m]
$12.58 m
[UI: $6.1 m- $222.1 m]
$50 i) Large impact on cost-
effectiveness from 
attributing a share of 
intervention costs to 
broader congestion, 
community & 
environmental objectives; 
ii) capacity utilisation not 
an issue for this 
intervention as 90% of 
costs are variable; and iii) 
cost data mostly 
modelled, not a strong 
empirical base.
8. Walking School Bus 
[Schools/neighbourhoods 
& community 
organisations].
Primary school children in 
Prep to Grade 2 (age 5-7 
years).
Number ≈ 7 840
$22.8 m
[UI: $16.6 m-$30.9 m]
$22.53 m
[UI: $16.35 m- $30.47 m]
$2908 i) Extensive set-up & 
overhead costs; ii) poor 
capacity utilisation; iii) 
attribution of costs to non 
obesity objectives; iv) 
empirical data coming 
from early developmental 
period of WSB program in 
Vic, Australia.
9. Reduction of TV 
advertising of high fat and/
or high sugar foods & 
drinks to children [Media 
& marketing].
All Australian children 
aged 5-14 years.
Number ≈ 2.4 million
$0.13 m
[UI: $0.12 m-$0.14 m]
($299 m)
[UI: net saving of between 
$133 m- $484 m]
$0.54 Key issue is exclusion of 
costs other than cost of 
monitoring/enforcing 
compliance with revised 
regulation. Excluded costs 
include: changing the 
regulations; any additional 
food costs to families in 
switch from non-core to 
core; impact on revenue 
stream of advertising 
companies & producers of 
non-core foods.
10. Family-based GP 
program targeted at 
overweight and 
moderately obese 
children [Primary care 
services g]
Overweight or moderately 
obese children aged 5-9 
years
Number ≈ 9 685
$6.3 m
[UI: $5.3 m-$7.4 m]
$2.95 m
[UI: net saving of $1.06 m 
to net cost of $7.0 m]
$650 i) Intervention design 
includes costs of family 
participation, but no 
additional benefits are 
included from weight loss 
to family members other 
than the child; ii) potential 
for piggy-backing this 
intervention into other 
GP-based interventions; 
iii) low % of fixed costs 
means cost drivers for 
affordability (patient 
numbers), do not impact 
much on cost-
effectiveness; and iv) 
majority of cost incurred 
by government, but cost 
impact on family still 
significant, with time costs 
a major factor.
Table 1: Evaluation design frame for interventions chosen (Continued)BMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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11. Family-based targeted 
program for obese 
children [Primary care 
services9 + hospital setting 
delivery by 
multidisciplinary team]
Obese children aged 10-11 
years.
Number ≈ 5 800
$11.0 m
[UI: $6.8 m-$18.3 m]
($4.0 m)
[UI: net saving of $19.0 m 
to net cost of $2.4 m]
$1,896 i) Recruitment component 
adjusted from screening in 
schools in RCT, to 
opportunistic recruitment 
via GPs; ii) assumed 50% 
of 6,000 GPs already have 
calibrated scales and 
stadiometers necessary to 
measure weight; iii) 
'intention to treat' 
approach adopted for 
costing (i.e. non 
completion still involved 
intervention costs), but 
full completion of visits 
required before benefits 
attributed.
12. Orlistat therapy for 
obese adolescents 
[Primary care services9].
Obese adolescents aged 
12-16 years.
Number ≈ 3 256
$6.3 m
[UI: $1.4 m-$20.0 m]
$4.9 m
[UI: $1.1 m-$15.9 m]
$1,935 i) Modelling incorporated 
opportunistic recruitment 
in Australian primary care 
setting (by GPs with 
dieticians providing 
dietary advice) and 
conservative adherence 
rates (65%); ii) only 
patients responsive to 
Orlistat assumed to 
continue past 2-week run-
in period; iii) costs to 
parents in accompanying 
adolescent included; iv) 
high proportion of costs 
falling on patients/families 
(as Orlistat not on 
Pharmaceutical Benefits 
Schedule) impacts on 
access.
13. Laparoscopic 
adjustable gastric banding 
(LAGB) for morbidly 
obese adolescents 
[Hospital10].
Severely obese adolescents, 
aged 14-19 years, with 
private health insurance
Number ≈ 4 120
$130 m
[UI: $52 m-$265 m]
$53.4 m
[UI: $20.1 m-$116.8 m]
$31,553 i) Definition of 'current 
practice'; ii) inclusion in 
costing of ongoing follow-
up, including regular 
consultations and 2 LAGB 
replacements over 
lifetime; iii) cost data 
coming from early 
developmental period of 
LAGB (case series of 28 
patients) extrapolated to 
eligible adolescent 
population; and iv) 
management of co-
morbidities assumed to be 
same for intervention and 
comparator.
Protocol issues common to all interventions: i) Inclusion of time costs for adults/carers, but not children/adolescents; ii) exclusion of production gains/loses; iii) 
exclusion of unrelated costs in rest of life; iv) 'steady-state' costing, with program modeled in accordance with efficacy potential, assuming trained staff and infrastructure 
available; v) costs offsets based on mean reduction in BMI continuing over life of the child; vi) early set-up & development costs excluded (i.e. costs incurred before 
intervention commences, such as development of training packages); vii) annuitisation of capital, including human capital costs like training; and viii) full pathway costing, 
including recruitment and coordination.
Notes:
1 Current practice comparator defined as "no intervention" as programs either focussed on children previously inactive and/or minimal activity previously existed.
2 The intervention period is defined as one representative year of "steady-state" operation, with "rest-of-life" modelling for all associated costs and benefits.
3 Number of children participating in the intervention based on Australian population figures in 2001 and likely take-up rates. For some interventions, not all of the children/
adolescents participating receive a health benefit from the intervention.
4Cost per child estimates do not include cost offsets.
5 Includes child care centres, family day care and outside school hours care.
6 95% uncertainty interval
7 Includes State/Territory government, local government, community groups, recreation and sporting bodies, and private organisations.
8 Current regulations limit adverts to 5 minutes every 30 minutes during 5 hrs of designated child slots & prohibits advertisements during 2.5 hrs per week of designated pre-
school timeslots.
9 Includes general medical practice (GPs), community health centres and other community-based and private-sector services.
10 The hospital setting was not included in 'Healthy Weight 2008' [21], but this clinical intervention was included in the project for purposes of comparison and benchmarking.
Table 1: Evaluation design frame for interventions chosen (Continued)BMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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reported for the cohort of children eligible for a particular
intervention in the representative baseline year 2001. The
time horizon for the tracking of the costs and benefits aris-
ing from an intervention was the remaining life span of
the target cohort, i.e. until death or age 100 years. A cohort
multi-state life table approach was developed for this pur-
pose [8].
Regardless of the time horizon chosen, all interventions
were assumed to be in 'steady-state' operation, meaning
that they were working at their full effectiveness potential
and that trained personnel and/or infrastructure were
available, and set-up costs were excluded.
Discounting
Discounting at 3% per annum was applied to both costs
and benefits. This rate approximates the long term bond
rate, the rule of thumb often used in selecting the appro-
priate discount rate. It is also the rate recommended by a
consensus panel of health economists in the USA for cost-
effectiveness analysis [13].
Selection of interventions
The guiding economic principle of opportunity cost -- that
is, of benefit/benefit forgone in alternate uses of available
funds -- rests on the careful selection and specification of
current practice and options for change. The selection of
interventions for analysis was a difficult and time con-
suming task, given the limited evidence of effectiveness
and requirement for clear specification [8]. After discus-
sion, the Working Group agreed to the following selection
criteria:
1) relevance to current policy decision making;
2) availability of evidence of efficacy/effectiveness to
support meaningful analyses, using a broad definition
of evidence;
3) potential impact on addressing the problem of
obesity;
4) the ability to specify the intervention in clear con-
crete terms to facilitate meaningful evaluation;
5) inclusion of a mix of interventions ranging from
broad-based to narrower more specific interventions,
and across a range of settings (community, schools,
clinic, media); and
6) considerations of program logic.
The ACE-Obesity project had the resources over a two year
period to evaluate the effectiveness and cost-effectiveness
of 13 different obesity interventions in children and ado-
lescents (Additional File 1). Priority was given to public
health interventions that met 'relevance to current policy
decision making' and 'availability of evidence to support
the analyses'. Discussion around reasons for exclusion of
other interventions can be found in Haby et al [8].
Assessment of health benefits
DALYs saved over the child's lifetime was chosen as the
measure of health gain. The methods for calculating the
impact of the intervention on the Body Mass Index (BMI)
post-intervention and then DALYs saved over the lifetime
of the target population are described fully in Haby et al
[8].
Assessment of costs
A common convention in costing is to describe the analy-
sis in three steps; identification, measurement and valua-
tion [12].
Step One ~ Identification of costs
For the identification step, the societal perspective
adopted means that costs to both public health care pro-
viders (Commonwealth, State and Territory governments)
and private sector (clients/participants, their family/car-
ers) were included, as well as costs to sectors other than
health (for example, education and infrastructure).
The potential impacts of interventions on production in
the general economy due to early return to work or
reduced disease incidence (production losses/gains) were
not included in ACE-Obesity, but are currently the basis of
a separate study [14]. The inclusion of unrelated health
care costs in additional years of life conferred by an inter-
vention is a contentious issue amongst economists
[12,13] and such costs were not included. While time
costs for adults were included (e.g. parents and/or volun-
teers supporting an intervention), no allowance was made
for the time costs of children and adolescents participat-
ing in an intervention.
Step Two ~ Measurement of costs
This step measures the quantities of resource used that
stem from the intervention and its downstream effects.
(i) Intervention costs
Detailed pathway analysis was undertaken for each of the
interventions. This entailed determining the probability
of certain activities occurring and specifying the resources
used in association with those activities. It was assumed
that participants who did not adhere to the intervention
incurred the intervention costs but received no benefit.
One major issue of concern to accurate measurement was
the attribution of costs to an intervention in situations
where resources were jointly used by one or more pro-
grams. For example, in interventions in the school setting,BMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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the costs of teachers, materials and equipment may be
shared by several programs. The criteria used to distribute
such joint costs were tabulated and varied under sensitiv-
ity analysis so that users of the study results can satisfy
themselves that they were reasonable.
(ii) Cost offsets
Cost offsets are savings in future health sector expenditure
that can be attributed to the reduction in BMI due to an
intervention. Health sector expenditure for obesity-related
diseases, calculated by the Australian Institute of Health
and Welfare, was used [15]. These disease specific esti-
mates are satellite estimates of the main health expendi-
ture estimates and are based on a national accounts
approach. They include expenditure on health goods and
services, health-related services and health-related invest-
ment. They do not include:
￿ expenditure that may have a 'health' outcome but which
is undertaken outside the health sector, such as expendi-
ture on building safer transport systems or the education
of health professionals;
￿ expenditure on personal activities not directly related to
maintaining or improving personal health;
￿ expenditure that does not have health as the main area
of expected national benefit; or
￿ time costs.
It was assumed that the current (2001) average costs and
clinical practice would be representative of future costs
and practices.
To determine the reduction in obesity-related costs for a
particular intervention, we used the same methods as
used for the calculation of DALYs saved [8]. In summary,
we first converted the total current costs for each obesity-
related disease for each sex and 10-year age group, to rates
by dividing by 2001 Australian population figures and
applying these to each of the two 5-year age groups within
the 10-year age group. Disease-specific rates were summed
to give total cost rates for obesity-related diseases for each
sex and 5-year age group. Total cost rates were extrapo-
lated from 5-year to 1-year age groups for input into the
base case life table using linear interpolation between data
points. The change in the current and future BMI distribu-
tion of the target population due to the intervention was
used to determine the potential impact fraction (PIF) for
each 5-year age group and for males and females sepa-
rately. The disease-specific cost rates for the intervention
scenario were calculated as the base case cost rate x (1-PIF)
for each age and sex category before input into the inter-
vention life table. The difference between the base case
and the intervention scenario gives the total obesity-
related costs saved (cost-offsets). This difference was
applied to the total population benefiting from the inter-
vention to get total cost-offsets.
Step Three ~ Valuation of costs
In the valuation step, a unit price for each of the activities,
together with the data source, was specified. Costs were
measured in real prices for the reference year (2001). As
interventions fell largely outside the health sector, adjust-
ment was made using the relevant Consumer Price Index
[16] rather than a health inflator. Intervention costs to the
government health sector, clients/families, and non-
health sectors were identified, measured and reported sep-
arately.
Incremental cost effectiveness ratios (ICERs)
The cost-effectiveness ratios were determined as the incre-
mental cost of the intervention divided by the incremental
benefit and presented as cost (AUD) per DALY saved
(both with and without cost offsets). In related articles the
full cost-effectiveness results for each intervention
assessed are presented and analysed in detail. The 'best
options' are defined as interventions which are cost-effec-
tive as measured by the commonly used benchmark for
cost-effectiveness in Australia of less than $50,000 per
DALY (disability-adjusted life-year saved).
Uncertainty testing and sensitivity analysis
Extensive 'uncertainty testing' was conducted to cover var-
iation in those technical parameters (usually economic
and epidemiological inputs) that have an impact on effi-
cacy/effectiveness, unit costs, etc. 'Sensitivity testing', on
the other hand, was defined to cover variation in key
design features of an intervention, such as the delivery
mode or the target age group and joint attribution of
costs.
Simulation-modelling techniques (with Monte Carlo
sampling) using @Risk software [17] were used to allow
the presentation of the 95% uncertainty range around the
benefits, costs and cost-effectiveness ratios. This approach
is recommended by the Canadian Coordinating Office for
Health Technology Assessment [18] and the US Consen-
sus Panel on Cost-Effectiveness in Health and Medicine
[13]. The probability distributions around the input vari-
ables were based on standard errors or the range of param-
eter values quoted in, or calculated from, the literature;
and/or from expert advice on the likely scenarios under
Australian conditions. The @RISK analysis also showed
the input parameters with the greatest influence on the
final results and hence provided an indication of research
priorities if greater accuracy of results was desired.BMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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The 2nd Stage Filter Criteria
The 2nd stage filter analysis involved the assessment of
issues that either influence the degree of confidence that
can be placed in the cost-effectiveness ratios (such as the
level of available evidence), or broader issues that need to
be taken into account in decision-making about resource
allocation. The filters used in the ACE-Obesity study were
equity, strength of evidence, feasibility of implementa-
tion, acceptability to stakeholders, sustainability, and
potential for side effects (Moodie et al 2009 as yet unpub-
lished).
Results
The costs for the 13 modelled interventions varied consid-
erably, both in absolute terms and when expressed as a
'cost per child' estimate (refer Table 1). In terms of gross
cost (i.e. ignoring potential cost offsets), costs for applica-
tion Australia-wide, varied from AUD130m per annum
(lap banding for severely obese adolescents), to less than
AUD1m per annum (controlling TV advertising of 'junk
food'; targeted multi-faceted school-based program), rais-
ing affordability as an important issue for policy-makers
to consider. There were 3 interventions of high cost in
Australian terms (i.e. >AUD40m per annum); 6 interven-
tions of moderate cost (i.e. AUD10m-40m per annum;
and 4 interventions of low cost (i.e. <AUD10m per
annum).
When potential cost offsets were included, however, the
results changed considerably for some interventions. One
high cost intervention moved to a net saving (multi-fac-
eted school-based with physical activity); three moderate
cost interventions moved to a net saving (education to
reduce carbonated drinks in schools; family-based tar-
geted program for obese children; education program to
reduce TV viewing); and two low cost interventions
moved to a net saving (regulation of TV advertising; tar-
geted multi-faceted school-based program). For those
moderate to high cost interventions where potential cost
offsets were small, this was because anticipated health
impacts were small (as health impacts and cost offsets are
correlated), and the combination of moderate to high
costs with small health gains, meant achieving cost-effec-
tiveness (i.e. less than AUD50,000 per DALY) was likely to
be a challenge.
Expressing costs as a 'net cost per child' adds the impor-
tant dimension of intervention reach and loading, to bal-
ance the simple focus on total costs. Some moderate to
high cost interventions perform quite strongly on this
indicator (Active After School Communities; TravelSmart;
education to reduce TV viewing), as the setting and nature
of the intervention mean that large numbers of children
have access and/or capacity utilisation is stronger.
Detailed cost effectiveness and 2nd stage filter results for
each intervention will be published in upcoming papers.
Discussion
The high variability in the cost results summarised in
Table 1 raises affordability as a major policy considera-
tion, in addition to concerns for effectiveness, efficiency
and equity of access. In interpreting these cost results it is
important to understand the impact of three key factors:
first, the way in which the cost results are reported, which
will suggest different take-home messages (i.e. 'gross cost',
'net cost' or 'cost per child'); second, the impact of inter-
vention-specific factors which clearly vary between inter-
ventions (refer 'Key cost issues' column of Table 1); and
third, the impact of the evaluation protocol which is com-
mon to all the interventions evaluated and affects each in
much the same way (refer last row of Table 1).
Reporting costs as 'gross costs' (i.e. ignoring potential cost
offsets) is important, because from a policy perspective, it
closely approximates the financial budget that will be
needed to operate the interventions. Reporting 'net costs'
is important because cost offsets have a major influence
on cost-effectiveness, as well as the ongoing budget impli-
cations of funding interventions over the longer term. The
role of cost offsets will focus decision-makers on their
achievability, as well as foster a concern for who receives
those cost offsets. Reporting costs as a 'net cost per child'
adds the important dimension of intervention reach and
loading, which is a useful process indicator, but should
not be confused with the higher order efficiency of achiev-
ing outcomes. Some interventions with low 'cost per
child' results, for example, may still be ineffective in
achieving BMI reductions (e.g. TravelSmart), while some
with high 'cost per child' results could be very effective in
achieving health gains (e.g. Lap Banding). Thus high 'costs
per child' results reflect factors like total cost, targeting and
capacity utilisation, but are not necessarily synonymous
with poor cost-effectiveness.
Turning to the intervention-specific factors, it is clear that
some interventions are over-burdened with extensive
coordination and overhead costs, particularly when com-
bined with poor utilisation of available capacity (e.g.
Walking School Bus; Active After School Communities).
As this situation applies to important current government
initiatives at both the Commonwealth and State levels, we
have undertaken careful examination of these cost struc-
ture and utilisation factors. The counterpoint to this
observation is that some interventions have multiple
objectives that include broader traffic congestion, com-
munity and environment goals (eg. TravelSmart, Walking
School Bus). When a share of costs is attributed to these
broader objectives, then cost performance is improved
and/or affordability may be shared across a number ofBMC Public Health 2009, 9:419 http://www.biomedcentral.com/1471-2458/9/419
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portfolios. Another important cost factor to consider is
the potential to combine interventions or piggyback them
on to existing programs (e.g. family-based GP program for
moderately obese children).
In terms of the cost protocol, key points to note are the
inclusion of time costs for adults; the assumption of
'steady-state' costing; the annuitisation of capital items
(equivalent to a lease); and the approach to cost offsets.
The 'steady-state' assumption means that the technical
analyses did not include a detailed 'roll-out phase' and did
not address implementation or 'learning curve' issues.
This reflects the priority setting context of the analyses,
where multiple interventions are being assessed, and the
research question is framed in terms of the potential cost-
effectiveness of interventions if they are implemented in
accordance with their effectiveness potential. This does
not mean, however, that practical issues related to the fea-
sibility and acceptability of implementation are ignored -
rather, they are considered in the 2nd stage filter analysis.
The 'steady-state' assumption keeps the technical analysis
tractable and achieves comparability in the results across
multiple interventions.
There are several limitations in our approach to the calcu-
lation of cost offsets. Firstly, the cost offsets are based on
the mean reduction in BMI continuing over the life of
child (bias towards over-estimation) [19,20]. The
reported cost-offset results are dependent on this mainte-
nance of benefit assumption. We have acknowledged that
there is a potential danger for this assumption to over-esti-
mate the cost-effectiveness results, but were constrained
by the lack of evidence to the contrary in children. This
will be addressed in individual papers where the sensitiv-
ity of results to this assumption will be explored.
In addition, cost offsets use a health sector rather than a
societal perspective (bias towards under-estimation); time
costs and other patient specific costs (eg travel costs) are
not included in the health expenditure accounts; and not
all health care expenditure could be allocated to specific
diseases (around 13% involving ambulance assistance;
aids and appliances; and aspects of community health),
and as a result was not included (bias towards under-esti-
mation). It is difficult to predict with any certainty the net
effects of these biases.
Turning to the broader issue of the ACE approach to pri-
ority setting, the strengths of the ACE-Obesity study
include an evidence-based approach; the use of a com-
mon economic protocol to ensure comparability of the
results; extensive uncertainty and sensitivity testing; inter-
pretation of cost-effectiveness ratios within a broader
decision-making framework that includes consideration
of second stage filter criteria; and the use of local data for
demography, health system costs and offsets, disease inci-
dence/prevalence, risk factors and disease burden [9].
The main limitations of the ACE-Obesity study relate to
evidence of effectiveness which was discussed in detail in
Haby et al[8] We use the Australian context to determine
the health benefits, costs and incremental cost-effective-
ness ratios. Therefore, care must be taken if trying to gen-
eralise the results to other countries. Some interventions
may work differently in other countries due to differences
in lifestyle, culture, beliefs and current practice in obesity
prevention. The costs of implementing the interventions
are also likely to vary between countries due to differences
in salary structures, health systems, other unit costs and
methods of implementation. The impact on total BMI
units saved, DALYs averted and cost offsets will also vary
according to differences in population size and structure
and different disease rates between countries.
Conclusion
Despite the current limitations in evidence, the ACE-
Obesity study provides useful information for policy-
makers. To our knowledge there have been no similar
attempts at determining affordability and effectiveness of
interventions across a wide range of obesity interventions
in a comparable manner. Despite considerable uncer-
tainty around key input variables, clear distinctions in cost
between obesity interventions were found, together with
logical explanations for the differentials. Nevertheless,
until there is greater evidence, including better evalua-
tions of new and current interventions for preventing
overweight and obesity, many of our estimates should be
considered provisional, though strongly indicative of the
relative magnitude of the health gain and costs. For some
interventions, particularly those which are currently
funded, our work indicates areas where cost performance
could be carefully studied, with a view to improvements
in cost structure and capacity utilisation.
We hope the publication of individual intervention in
future papers results will both encourage debate about
future directions for health policy, and encourage further
research to clarify those issues where current knowledge is
lacking.
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